Modifier genes in cystic fibrosis

Pediatric Pulmonology

Volumn 39, Issue 5, 2005, Pages 383-391

  Davies, J C ^a,b,c   Griesenbach, U ^a   Alton, Eric ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Haplotype; Inflammation; Lung function; Phenotype; Polymorphism

Indexed keywords

ALPHA 1 ANTITRYPSIN; BETA ADRENERGIC RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE TRANSFERASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE BINDING LECTIN; MANNOSE BINDING LECTIN 2; MUCIN; NEURONAL NITRIC OXIDE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; AIRWAY; CYSTIC FIBROSIS; ENVIRONMENTAL FACTOR; GASTROINTESTINAL DISEASE; GENE MUTATION; GENE TARGETING; HOST RESISTANCE; HUMAN; HUMAN TISSUE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENOTYPE; HUMANS; PHENOTYPE; POLYMORPHISM, GENETIC; RESEARCH DESIGN; VARIATION (GENETICS);

EID: 17444400836     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.20198     Document Type: Review

References (64)

1. Chen X, Sullivan PF. Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput. Pharmacogenomics J 2003;3:77-96.
2. Rubinsztein DC, Easton DF. Apolipoprotein E genetic variation and Alzheimer's disease. A meta-analysis. Dement Geriatr Cogn Disord 1999;10:199-209.
3. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
4. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
5. Sato H, Grutters JC, Pantelidis P, Mizzon AN, Ahmad T, Van Houte AJ, Lammers JW, Van Den Bosch JM, Welsh KI, Du Bois RM. HLA-DQB1*0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol 2002;27:406-412.
6. Kawabata Y, Ikegami H, Kawaguchi Y, Fujisawa T, Hotta M, Ueda H, Shintani M, Nojima K, Ono M, Nishino M, Taniguchi H, Noso S, Yamada K, Babaya N, Ogihara T. Age-related association of MHC class I chain-related gene A (MICA) with type 1 (insulin-dependent) diabetes mellitus. Hum Immunol 2000;61:624-629.
7. Iacopetta B, Grieu F, Joseph D. The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br J Cancer 2004;90:419-422.
8. Boekholdt SM, Peters RJ, de Maat MP, Zwinderman AH, Der Wall EE, Reitsma PH, Jukema JW, Kastelein JJ. Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular events. Am Heart J 2004;147:181-186.
9. Romieu I, Sienra-Monge JJ, Ramirez-Aguilar M, Moreno-Macias H, Reyes-Ruiz NI, Estela del Rio-Navarro B, Hernandez-Avila M, London SJ. Genetic polymorphism of GSTM1 and antioxidant supplementation influence lung function in relation to ozone exposure in asthmatic children in Mexico City. Thorax 2004;59:8-10.
10. Goetz MP, Ames MM, Weinshilboum RM. Primer on medical genomics. Part XII: pharmacogenomics-general principles with cancer as a model. Mayo Clin Proc 2004;79:376-384.
11. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073.
12. Welsh M, Ramsey BW, Accurso F, Cutting GR. Cystic fibrosis. In: Scriver AB, Sly WS, Valle D, editors. The molecular and metabolic basis of inherited disease. New York: McGraw-Hill; 2001. p 5121-5188.
13. Santis G, Osborne L, Knight RA, Hodson ME. Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosis. Lancet 1990;336:1081-1084.
14. Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, Tsui LC, Durie P. The relation between genotype and phenotype in cystic fibrosis-analysis of the most common mutation (delta F508). N Engl J Med 1990;323:1517-1522.
15. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003;361:1671-1676.
16. Bronsveld I, Mekus F, Bijman J, Ballmann M, de Jonge HR, Laabs U, Halley DJ, Ellemunter H, Mastella G, Thomas S, Veeze HJ, Tummler B. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest 2001;108:1705-1715.
17. Noone PG, Pue CA, Zhou Z, Friedman KJ, Wakeling EL, Ganeshananthan M, Simon RH, Silverman LM, Knowles MR. Lung disease associated with the IVS8 5T allele of the CFTR gene. Am J Respir Crit Care Med 2000;162:1919-1924.
18. Groman JD, Hefferon TW, Casals T, Bassas L, Estivill X, Des GM, Guittard C, Koudova M, Fallin MD, Nemeth K, Fekete G, Kadasi L, Friedman K, Schwarz M, Bombieri C, Pignatti PF, Kanavakis E, Tzetis M, Schwartz M, Novelli G, D'Apice MR, Sobczynska-Tomaszewska A, Bal J, Stuhrmann M, Macek M Jr, Claustres M, Cutting GR. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 2004;74:176-179.
19. Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, Jorissen M, Droogmans G, Reynaert I, Goossens M, Nilius B, Cassiman JJ. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 1998;101:487-496.
20. Dork T, Wulbrand U, Richter T, Neumann T, Wolfes H, Wulf B, Maass G, Tummler B. Cystic fibrosis with three mutations in the cystic fibrosis transmembrane conductance regulator gene. Hum Genet 1991;87:441-446.
21. Romey MC, Guittard C, Chazalette JP, Frossard P, Dawson KP, Patton MA, Casals T, Bazarbachi T, Girodon E, Rault G, Bozon D, Seguret F, Demaille J, Claustres M. Complex allele [-102T>A+S549R(T>G)] is associated with milder forms of cystic fibrosis than allele S549R(T>G) alone. Hum Genet 1999;105:145-150.
22. Boyle MP. Nonclassic cystic fibrosis and CFTR-related diseases. Curr Opin Pulm Med 2003;9:498-503.
23. Koch C, Hoiby N. Pathogenesis of cystic fibrosis. Lancet 1993;341:1065-1069.
24. Mahadeva R, Lomas DA. Genetics and respiratory disease. 2. Alpha 1-antitrypsin deficiency, cirrhosis and emphysema. Thorax 1998;53:501-505.
25. Birrer P, McElvaney NG, Rudeberg A, Sommer CW, Liechti-Gallati S, Kraemer R, Hubbard R, Crystal RG. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994;150:207-213.
26. Doring G, Krogh-Johansen H, Weidinger S, Hoiby N. Allotypes of alpha 1-antitrypsin in patients with cystic fibrosis, homozygous and heterozygous for deltaF508. Pediatr Pulmonol 1994;18:3-7.
27. Mahadeva R, Westerbeek RC, Perry DJ, Lovegrove JU, Whitehouse DB, Carroll NR, Ross-Russell RI, Webb AK, Bilton D, Lomas DA. Alpha1-antitrypsin deficiency alleles and the Taq-I G→A allele in cystic fibrosis lung disease. Eur Respir J 1998;11:873-879.
28. Mahadeva R, Sharples L, Ross-Russell RI, Webb AK, Bilton D, Lomas DA. Association of alpha(1)-antichymotrypsin deficiency with milder lung disease in patients with cystic fibrosis. Thorax 2001;56:53-58.
29. Mahadeva R, Stewart S, Bilton D, Lomas DA. Alpha-1 antitrypsin deficiency alleles and severe cystic fibrosis lung disease. Thorax 1998;53:1022-1024.
30. Henry MT, Cave S, Rendall J, O'Connor CM, Morgan K, FitzGerald MX, Kalsheker N. An alpha 1-antitrypsin enhancer polymorphism is a genetic modifier of pulmonary outcome in cystic fibrosis. Eur J Hum Genet 2001;9:273-278.
31. Frangolias DD, Ruan J, Wilcox PJ, Davidson AG, Wong LT, Berthiaume Y, Hennessey R, Freitag A, Pedder L, Corey M, Sweezey N, Zielenski J, Tullis E, Sandford AJ. Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am J Respir Cell Mol Biol 2003;29:390-396.
32. Aron Y, Polla BS, Bienvenu T, Dall'ava J, Dusser D, Hubert D. HLA class II polymorphism in cystic fibrosis. A possible modifier of pulmonary phenotype. Am J Respir Crit Care Med 1999;159:1464-1468.
33. Aron Y, Bienvenu T, Hubert D, Dusser D, Dall'Ava J, Polla BS. HLA-DR polymorphism in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1999;104:891-892.
34. Greally P, Hussein MJ, Cook AJ, Sampson AP, Piper PJ, Price JF. Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child 1993;68:389-392.
35. Hull J, Thomson AH. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax 1998;53:1018-1021.
36. Arkwright PD, Pravica V, Geraghty PJ, Super M, Webb AK, Schwarz M, Hutchinson IV. End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms. Am J Respir Crit Care Med 2003;167:384-389.
37. Low T, Lympany PA, Davies JC, Griesenbach U, Shen N, Escudero Garcia SI, Somerton LA, Welsh KI, Geddes DM, du Bois RM, Alton EWFW. The effect of polymorphisms in inflammatory mediators on clinical phenotype in CF. Pediatr Pulmonol [Suppl] 2003;25:219.
38. Grasemann H, Knauer N, Buscher R, Hubner K, Drazen JM, Ratjen F. Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene. Am J Respir Crit Care Med 2000;162:2172-2176.
39. Grasemann H, van's Gravesande KS, Buscher R, Knauer N, Silverman ES, Palmer LJ, Drazen JM, Ratjen F. Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167:390-394.
40. Forstermann U, Boissel JP, Kleinen H. Expressional control of the "constitutive" isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998;12:773-790.
41. Accurso FJ, Sontag MK. Seeking modifier genes in cystic fibrosis. Am J Respir Crit Care Med 2003;167:289-290.
42. Mekus F, Tummler B. Cystic fibrosis and NOS3. Am J Respir Crit Care Med 2004;169:319-320.
43. Arkwright PD, Laurie S, Super M, Pravica V, Schwarz MJ, Webb AK, Hutchinson IV. TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 2000;55:459-462.
44. Wojnarowski C, Frischer T, Hofbauer E, Grabner C, Mosgoeller W, Eichler I, Ziesche R. Cytokine expression in bronchial biopsies of cystic fibrosis patients with and without acute exacerbation. Eur Respir J 1999;14:1136-1144.
45. Turner MW. The role of mannose-binding lectin in health and disease. Mol Immunol 2003;40:423-429.
46. Garred P, Pressler T, Madsen HO, Frederiksen B, Svejgaard A, Hoiby N, Schwartz M, Koch C. Association of mannose-binding lecting gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999;104:431-437.
47. Gabolde M, Giulloud-Bataille M, Feingold J, Besmond C. Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study. Br Med J [clin Res] 1999;319:1166-1167.
48. Buranawuti K, Cheng S, Merlo C, Zeitlin P, Rosenstein B, Mogayzel P, Wang X, Boyle M, Cutting G. Variants in the mannose binding lectin gene modify survival of cystic fibrosis patients. Pediatr Pulmonol [Suppl] 2003;25:215.
49. Davies JC, Johnson MM, Booth C, Fidler K, Bush A, Geddes DM, Alton EWFW, Turner M, Klein N. Age-specific effect of the cystic fibrosis modifier gene, MBL-2. Pediatr Pulmonol [Suppl] 2002;23:223.
50. Garred P, Pressler T, Lanng S, Madsen HO, Moser C, Laursen I, Balstrup F, Koch C. Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Pediatr Pulmonol 2002;33:201-207.
51. Ramsay CE, Hayden CM, Tiller KJ, Burton PR, Goldblatt J, Lesouef PN. Polymorphisms in the beta2-adrenoreceptor gene are associated with decreased airway responsiveness. Clin Exp Allergy 1999;29:1195-1203.
52. Taouil K, Hinnrasky J, Hologne C, Corlieu P, Klossek JM, Puchelle E. Stimulation of beta 2-adrenergic receptor increases cystic fibrosis transmembrane conductance regulator expression in human airway epithelial cells through a cAMP/protein kinase A-independent pathway. J Biol Chem 2003;278:17320-17327.
53. Buscher R, Eilmes KJ, Grasemann H, Torres B, Knauer N, Sroka K, Insel PA, Ratjen F. Beta2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. Pharmacogenetics 2002;12:347-353.
54. Wilson NM, Lamprill JR, Mak JC, Clarke JR, Bush A, Silverman M. Symptoms, lung function, and beta2-adrenoceptor polymorphisms in a birth cohort followed for 10 years. Pediatr Pulmonol 2004;38:75-81.
55. Turner SW, Khoo SK, Laing IA, Palmer LJ, Gibson NA, Rye P, Landau LI, Goldblatt J, Le Souef PN. Beta2 adrenoceptor Arg16Gly polymorphism, airway responsiveness, lung function and asthma in infants and children. Clin Exp Allergy 2004;34:1043-1048.
56. Eggermont E. Gastrointestinal manifestations in cystic fibrosis. Eur J Gastroenterol Hepatol 1996;8:731-738.
57. Rozmahel R, Wilschanski M, Matin A, Plyte S, Oliver M, Auerbach W, Moore A, Forstner J, Durie P, Nadeau J, Bear C, Tsui LC. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 1996;12:280-287.
58. Zielenski J, Corey M, Rozmahel R, Markiewicz D, Aznarez I, Casals T, Larriba S, Mercier B, Cutting GR, Krebsova A, Macek M Jr, Langfelder-Schwind E, Marshall BC, DeCelie-Germana J, Claustres M, Palacio A, Bal J, Nowakowska A, Ferec C, Estivill X, Durie P, Tsui LC. Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet 1999;22:128-129.
59. Duthie A, Doherty DG, Donaldson PT, Scott-Jupp R, Tanner MS, Eddleston AL, Mowat AP. The major histocompatibility complex influences the development of chronic liver disease in male children and young adults with cystic fibrosis. J Hepatol 1995;23:532-537.
60. Gabolde M, Hubert D, Guilloud-Bataille M, Lenaerts C, Feingold J, Besmond C. The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis. J Med Genet 2001;38:310-311.
61. Mekus F, Laabs U, Veeze H, Tummler B. Genes in the vicinity of CFTR modulate the cystic fibrosis phenotype in highly concordant or discordant F508del homozygous sib pairs. Hum Genet 2003;112:1-11.
62. Morgan TM, Coffey CS, Krumholz HM. Overestimation of genetic risks owing to small sample sizes in cardiovascular studies. Clin Genet 2003;64:7-17.
63. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 1996;21:267-275.
64. Gill D, Ethics Working Group of the Confederation of European Specialists in Paediatrics. Ethical principles and operational guidelines for good clinical practice in paediatric research. Recommendations of the Ethics Working Group of the Confederation of European Specialists in Paediatrics (CESP). Eur J Pediatr 2004;163:53-57.